Skip to main content

Table 5 Logistic regression model showing factors associated with clinically relevant fibrosis at end of study follow-up (N = 2419)

From: Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada

 APRI> 1.5 (clinically relevant fibrosis) at end of follow-up
Univariate AnalysisMultivariable Analysis
VariableOR95% CIWald pOR95% CIWald p
Hepatitis B
 Never co-infected Reference   
 Ever co-infected2.001.13–3.530.02   
Hepatitis C
 Never co-infected Reference  Reference 
 Ever co-infected7.034.61–10.74< 0.00016.354.12–9.79< 0.0001
Baseline AIDS
 No ADI ever Reference    
 None before/at FARVDT1.720.69–4.310.41  
  ≥ 1 before/at FARVDT1.950.73–5.19    
 White Reference    
Birth sex
 Female Reference   
 BC Reference    
Years on ARV0.970.92–1.020.26  
Age at first ARV1.010.99–1.020.21  
MSM0.340.26–0.60< 0.0001  
PWID5.053.37–7.56< 0.0001  
Baseline HIV viral load (Log10 copies/mL)  0.17   
  < 4 Reference   
  > 51.870.94–3.74    
Follow-up HIV viral load (Log10 copies/mL)
  < 4 Reference  Reference 
 4–53.331.54–7.16< 0.00012.271.01–5.10< 0.0001
  > 58.804.41–17.43 7.333.46–15.51 
Baseline CD4 count (cells/mm3)
  ≤ 100 Reference  Reference 
 200–3490.550.35–0.86 0.620.38–0.99 
  > 5000.370.16–0.86 0.550.23–1.32 
  1. FARVDT first naïve ARV date, MSM Men who have Sex with Men, PWID People Who Infect Drugs
  2. BC British Colombia, ON Ontario, QC Quebec
  3. Variables considered in the multivariate model included: hepatitis B, hepatitis C, race, province, age at first ARV treatment, MSM, follow-up HIV viral load, baseline CD4 count. Due to co-linearity with hepatitis C, PWID was not included in the final model